Development of membrane-active peptide therapeutics in oncology |
| |
| Authors: | Charles H Chen Bing Zan Jakob P Ulmschneider William C Wimley Timothy K Lu Martin B Ulmschneider Liping Zhou |
| |
| Institution: | 1. Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Massachusetts, Boston, USA;2. School of Physics and Astronomy, Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China;3. Department of Biochemistry and Molecular Biology, Tulane University, LA, New Orleans, USA;4. Synthetic Biology Group, Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA;5. Department of Chemistry, King's College London, London, UK |
| |
| Abstract: | Membrane-active peptides play an essential role in many living organisms and their immune systems and counter many infectious diseases. Many have dual or multiple mechanisms and can synergize with other molecules, like peptides, proteins, and small molecules. Although membrane-active peptides have been intensively studied in the past decades and more than 3500 sequences have been identified, only a few received approvals from the US Food and Drug Administration. In this review, we investigated all the peptide therapeutics that have entered the market or were subjected to preclinical and clinical studies to understand how they succeeded. With technological advancement (e.g., chemical modifications and pharmaceutical formulations) and a better understanding of the mechanism of action and the potential targets, we found at least five membrane-active peptide drugs that have entered preclinical/clinical phases and show promising results for cancer treatment. We summarized our findings in this review and provided insights into membrane-active anticancer peptide therapeutics. |
| |
| Keywords: | membrane-active drug oncology oncolytic peptide peptide therapeutics |
|
|
